COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics

COMPASS Pathways PLC ADR (CMPS): $39.68

0.28 (+0.71%)

POWR Rating

Component Grades













CMPS Stock Price Chart Interactive Chart >

Price chart for CMPS

CMPS Price/Volume Stats

Current price $39.68 52-week high $61.69
Prev. close $39.40 52-week low $22.51
Day low $38.60 Volume 338,000
Day high $40.00 Avg. volume 428,510
50-day MA $35.61 Dividend yield N/A
200-day MA $0.00 Market Cap 1.58B

COMPASS Pathways PLC ADR (CMPS) Company Bio

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.

CMPS Latest News Stream

Event/Time News Detail
Loading, please wait...

CMPS Latest Social Stream

Loading social stream, please wait...

View Full CMPS Social Stream

Latest CMPS News From Around the Web

Below are the latest news stories about COMPASS Pathways plc that investors may wish to consider to help them evaluate CMPS as an investment opportunity.

COMPASS Pathways plc to participate in JMP Securities and H.C. Wainwright investor conferences

LONDON, June 08, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in two investor conferences in June. George Goldsmith, Chairman, CEO and Co-founder, and Lars Wilde, President, Chief Business Officer, and Co-founder, will be participating in a fireside chat at the JMP Securities Life Sciences Confer

Yahoo | June 8, 2021

Compass Pathways: Huge Growth Potential, But I'm Cautious

Photo by metamorworks/iStock via Getty Images Investment Thesis COMPASS Pathways (NASDAQ:CMPS) is trying to treat a problem that is untreatable for the most part. They are doing so in a transformative way that is unique compared to traditional treatment methods. If COMPASS is able to successfully pass through its Phase...

Jamie Louko on Seeking Alpha | June 4, 2021

COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers

LONDON, June 03, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists. The data (see poster) from the randomised, dou

Yahoo | June 3, 2021

Psychedelic Company Forges Ahead in Developing New Treatments for Depression

Compass Pathways, the UK-based mental health care company that's innovating new mental health treatments, recently announced that it had been granted two new patents in the US. These patents cover the use of its oral formulations of synthetic psilocybin, the active ingredient in magic mushrooms, to treat major depressive disorder (MDD) and treatment-resistant depression (TRD). The new patents join Compass' first patent, granted for its methods of using COMP360, a synthetic psilocybin formulation

Yahoo | June 3, 2021

Investors think mind-bending drug DMT could rival psilocybin as a cost-effective psychedelic treatment for conditions like depression. 3 VCs explain why its fast-acting properties are appealing.

Summary List Placement An other-worldly experience is how users of psychedelic drug N,N-Dimethyltryptamine, or DMT, describe their high. The drug is gaining momentum among investors and biotech firms as a potential treatment for depression, anxiety, and other psychiatric conditions — one that could be far more cost-effective than other psychedelics. So far, most of the investment poured into psychedelic research has been for psilocybin — the psychoactive agent in magic mushrooms. And this industry is poised to boom: Compass Pathways, which is developing a synthetic form of psilocybin to treat depression, went public last September and is valued at $1.4 billion . Biopharma firm Atai Life Sciences, which invests in companies testing psilocybin therapies, has so far raised more than $360 m...

Business Insider | May 30, 2021

Read More 'CMPS' Stories Here

CMPS Price Returns

1-mo 15.38%
3-mo -6.33%
6-mo -28.44%
1-year N/A
3-year N/A
5-year N/A
YTD -16.71%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7425 seconds.